Results 151 to 160 of about 9,852 (179)

Cancer-associated SF3B1 mutations inhibit mRNA nuclear export by disrupting SF3B1–THOC5 interactions

The Journal of Biochemistry
Abstract Mutations in SF3B1 are common in many types of cancer, promoting cancer progression through aberrant RNA splicing. Recently, mRNA nuclear export has been reported to be defective in cells with the SF3B1 K700E mutation. However, the mechanism remains unclear.
Gang Liu, Bo Zhao, Yueru Shi, Youzhong Wan   +3 more
openaire   +2 more sources

Impact of SF3B1 mutation in myelofibrosis

Leukemia & Lymphoma, 2022
Jayastu Senapati, Srdan Verstovsek, Lucia Masarova, Naveen Pemmaraju, Keyur P. Patel, Guillermo Montalban-Bravo, Sherry A. Pierce, Lingsha Zhou, Guillermo Garcia-Manero, Hagop M. Kantarjian, Prithviraj Bose   +10 more
openaire   +2 more sources

101 SF3B1 Mutation and Overlapping Features of MDS/MPN-SF3B1-T and CLL: A Diagnostic Challenge

American Journal of Clinical Pathology
Abstract Introduction/Objective SF3B1 mutations are associated with several hematologic malignancies, including chronic lymphocytic leukemia (CLL) and myelodysplastic/myeloproliferative neoplasms with SF3B1 mutation and thrombocytosis (MDS/MPN-SF3B1-T). CLL cases with SF3B1 mutations often show
Zehra Kocas, Ali Tug, Jonathan Freeman
openaire   +1 more source

Comparison of the clinicopathological features in myeloproliferative or myelodysplastic neoplasms with SF3B1/JAK2, SF3B1/CALR, or SF3B1/MPL co-mutations.

Leukemia & lymphoma
Mutations in JAK2, CALR, and MPL account for over 90% of Philadelphia-negative (Ph-) myeloproliferative neoplasm (MPN), while SF3B1 mutations are diagnostic for myelodysplasia in myelodysplastic syndrome (MDS) or myelodysplastic/myeloproliferative neoplasm (MDS/MPN).
Richard, Shao, Le, Wang, Hailing, Zhang, Michael, Martin, Lynn, Moscinski, Amy, Li, Julie, Li, Jinming, Song   +7 more
openaire   +1 more source

Abstract 4350: Low frequencies of SF3B1 mutations indicate SF3B1 inhibitor as a novel moleculartargeted drug for colorectal cancer.

Cancer Research, 2013
Abstract Purpose: FR901464 (FR) is an antitumor agent that specifically binds to and inhibits the function of splicing factor 3B subunit 1 (SF3B1). Higher frequencies of SF3B1 gene mutations and their relevance to cancer progression have been shown in studies of hematological malignancies.
Tomoki Yamano, Hidenori Nakajima, Satoshi Tsuda, Shuji Kubo, Mie Hamanaka, Masayoshi Kobayashi, Daisuke Yamagishi, Takashi Kuno, Kiyoshi Tsukamoto, Astuko Tamamoto, Masafumi Noda, Nagahide Matsubara, Dave SB Hoon, Naohiro Tomita   +13 more
openaire   +1 more source

A Murine Model Harboring Cooperating DNMT3A and SF3B1 Mutations Phenocopies SF3B1 Driven Myelodysplastic Syndrome

Blood, 2022
Lashanale Wallace, Ana Leal-Cervantes, Amina Metidji, Jacquelyn Myers, Chandra Rolle, Heather Tillman, Esther A. Obeng   +6 more
openaire   +1 more source

m6A-driven SF3B1 translation control steers splicing to direct genome integrity and leukemogenesis

Molecular Cell, 2023
Gabriele Todisco, Cristian Bellodi, Marios Dimitriou   +2 more
exaly  

Cancer-associated mutations in SF3B1 disrupt the interaction between SF3B1 and DDX42

Journal of Biochemistry, 2022
Xin Hu, Youzhong Wan
exaly  

SF3B1 facilitates HIF1-signaling and promotes malignancy in pancreatic cancer

Cell Reports, 2022
Gerald Schwank, Chantal Pauli
exaly  

Anti-Sf3b1

Hybridoma and Hybridomics, 2003
openaire   +1 more source